Tagrisso approved in China as a 1st-line treatment for EGFR-mutated non-small cell lung cancer
In the Phase III FLAURA trial, Tagrisso significantly increased the time patients lived without disease progression versus the comparator Tagrisso is the only medicine demonstrating statistically-significant overall survival benefit in this settingAstraZeneca today announced that it has received marketing authorisation from China’s National Medical Products Administration (NMPA) for Tagrisso (osimertinib) as a 1st-line treatment for adults with locally-advanced or metastatic non-small cell lung cancer (NSCLC) whose tumours have the genetic mutations of epidermal growth factor receptor (